The biotechnology company Adocia, who made Monday's entry Nyse Euronext by scoring below its introductory course, wants to make innovations "low cost" in the field of diabetes you to facilitate their marketing in emerging markets, said its CEO told Reuters.
Gerard Soula, founder of the Lyon-based company has already signed a license agreement and collaboration with the U.S. pharmaceutical group Eli Lilly, said he could sign other agreements of this type in the next three years.
Created seven years ago, Adocia is the first introduction of 2012 in the Paris Bourse. Introduced in 15.88 euros, it was worth 14.87 euros to 14.30, showing a market capitalization of € 93.5 million.
The vocation of Adocia is to dismiss its technology to reformulate existing technologies to major industry players such as Novo Nordisk Diabetes, Eli Lilly and Sanofi that must revitalize a portfolio of insulin patents expire.
"The idea is to have formulations of existing products that can either change the frequency of administration, either to reduce the quantity of product for a better use of therapeutic proteins" , Gerard Soula explained in an interview.
"Until now, every innovation has justified increased costs. We say that there is no inevitability to this. We want to make innovations low cost because we know that emerging countries can not pay major innovations as the West. "
NOT RETURN MARKET
Adocia Strategy does not go directly to these markets but to lay off its technology to major players sector
. "We are a potential resource for these groups because they offer innovations on their own products, enabling them to offer higher performance rieures on areas or their own products expire, "said Gerard Soula.
Today there are 250 million diabetics worldwide and this figure will rise to 400 million within a decade, he said, adding that the share of emerging countries in this total is "huge", major problems arising from diabetes in China, India and South America.
The most advanced product of Adocia is a treatment for diabetic foot ulcer, for which the company will release third quarter 2012 a Phase III study in India could die butcher on marketing in 2014, said Gerard Soula. In this severe disease, Adocia chose to reformulate the Regranex, a Johnson & Johnson treatment.
The product, which would be recorded in emerging markets, must be manufactured in India, which will divide its price by three compared to U.S. prices while reducing manufacturing costs by 10, calculated Gerard Soula.
In addition, Adocia conducts tests to combine a rapid-acting insulin with Lantus, insulin slow Sanofi's patent must fall in 2015.
The goal is a formula to reduce to two the number of injections, against three to four a day now, said Gerard Soula, designed a marketing 2015-2016.
The market for insulin, an essential treatment for most diabetics, increased 10% in 2011 to 17 billion.
Adocia now has cash of 38 million euros. Strengthened by this, Gerard Soula said that with the partnership set up with Eli Lilly and capital raised through its IPO, Adocia would "not need to return to the market" for finance its projects.
Filed under: different, management, occupation, office, work by admin Comments Off